Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation
Metrics: PDF 1060 views | HTML 1388 views | ?
Yu-Hong Liu1, Julia Y.S. Tsang2, Yun-Bi Ni2, Thazin Hlaing3, Siu-Ki Chan4, Kui-Fat Chan5, Chun-Wai Ko2, S. Shafaq Mujtaba6 and Gary M. Tse2
1 Department of Pathology, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen, China
2 Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong
3 Department of Anatomic Pathology, Centro Hospitalar Conde de Sao Januario, Macao, SAR, China
4 Department of Pathology, Kwong Wah Hospital, Hong Kong
5 Department of Pathology, Tuen Mun Hospital, Hong Kong
6 Histopathology Section, Laboratory Department, King Abdullah Medical City, Makkah, Kingdom of Saudi Arabia
Gary M. Tse, email:
Keywords: doublecortin-like kinase 1, breast cancer, neuroendocrine differentiation, prognosis
Received: June 16, 2015 Accepted: November 15, 2015 Published: November 25, 2015
Doublecortin-like kinase 1 (DCLK1), a microtubule associated kinase, has recently been proposed to be a putative marker for stemness and adverse prognosis in gastrointestinal cancers. However, it is not clear whether the protein also plays similar roles in breast cancer. Here, the expression of DCLK1 was analyzed in a large cohort of invasive breast cancers (IBC) by immunohistochemistry. DCKL1 was associated with favorable clinico-pathologic features, namely lower histologic grade, absence of lymphovascular invasion, fibrotic focus, necrosis and lower pN stage (p≤0.045). Additionally, independent significant correlations were found with estrogen receptor and neuroendocrine markers (p ≤0.019), implicating its relationship with IBC with neuroendocrine differentiation (IBC-NED). In the current cohort, IBC-NED showed worse outcome than luminal cancers without NED (hazard ratio=1.756, p=0.041). Interestingly, within the IBC-NED group, DCLK1 was found to be a good prognostic factor (hazard ratio =0.288, p=0.011). These findings were in contrast to those in gastrointestinal cancers, suggesting different functional roles of DCLK1 in different types of cancers. In clinical practice, NED is not routinely assessed; thus IBC-NED are not well studied. Its poor outcome and significant heterogeneity warrants more attention. DCLK1 expression could aid in the prognostication and management of this special cancer subtype.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.